Ability Pharma closes €1.2-million round with Capital Cell

by Gemma Escarré,

Ability Pharma has raised €1,230,000 in crowdfunding through Capital Cell. This is the largest round the platform has raised so far. The campaign opened in early September.

This round is bridge funding towards a round to raise between €3 million and €5 million in venture capital to complete phase II clinical trials on the drug ABTL0812 for lung and endometrial cancer in Spain and France.

ABTL0812 is administered in combination with chemotherapy as a first-line therapy and maintenance therapy.

Both Ability Pharma and Capital Cell are members of CataloniaBio & HealthTech.

More information

Photo: Carles Domènech, CEO of Ability Pharma

Comments


To comment, please login or create an account